LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.
Insider & Institutional Ownership
54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 3.6% of Silo Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
LENZ Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| LENZ Therapeutics | -586.74% | -53.39% | -49.14% |
| Silo Pharma | -6,726.39% | -81.75% | -66.35% |
Earnings and Valuation
This table compares LENZ Therapeutics and Silo Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LENZ Therapeutics | $21.48 million | 7.43 | -$82.13 million | ($4.09) | -1.24 |
| Silo Pharma | $54,077.00 | 64.46 | -$4.23 million | ($4.36) | -0.50 |
Silo Pharma has lower revenue, but higher earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Silo Pharma, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for LENZ Therapeutics and Silo Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LENZ Therapeutics | 1 | 2 | 5 | 0 | 2.50 |
| Silo Pharma | 1 | 0 | 0 | 0 | 1.00 |
LENZ Therapeutics currently has a consensus price target of $28.80, suggesting a potential upside of 467.49%. Given LENZ Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe LENZ Therapeutics is more favorable than Silo Pharma.
Summary
LENZ Therapeutics beats Silo Pharma on 10 of the 13 factors compared between the two stocks.
About LENZ Therapeutics
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
About Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
